[HTML][HTML] Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis
Objectives Cytokine release syndrome with elevated interleukin-6 (IL-6) levels is associated
with multiorgan damage and death in severe coronavirus disease 2019 (COVID-19). Our …
with multiorgan damage and death in severe coronavirus disease 2019 (COVID-19). Our …
[HTML][HTML] Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review
Background Tocilizumab is an IL-6 receptor-blocking agent proposed for the treatment of
severe COVID-19. The aim of this systematic review was to describe the rationale for the use …
severe COVID-19. The aim of this systematic review was to describe the rationale for the use …
[HTML][HTML] The role of Interleukin 6 inhibitors in therapy of severe COVID-19
E Nasonov, M Samsonov - Biomedicine & Pharmacotherapy, 2020 - Elsevier
Cytokine storm syndrome (CSS) is a severe complication of inflammatory immune diseases
or treatment of malignancies; it may also appear during the progression of COVID-19. CSS …
or treatment of malignancies; it may also appear during the progression of COVID-19. CSS …
Immunosuppressive drugs and COVID-19: a review
TS Schoot, APM Kerckhoffs, LB Hilbrands… - Frontiers in …, 2020 - frontiersin.org
Background Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2). It is currently unknown whether …
syndrome coronavirus 2 (SARS-CoV-2). It is currently unknown whether …
Efficacy of tocilizumab in COVID‐19: a systematic review and meta‐analysis
The efficacy of tocilizumab (TOC), monoclonal antibody against interleukin‐6 (IL‐6) receptor,
in patients with coronavirus disease‐2019 (COVID‐19) patients has led to conflicting results …
in patients with coronavirus disease‐2019 (COVID‐19) patients has led to conflicting results …
Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19
Background There is accumulating evidence for an overly activated immune response in
severe COVID-19, with several studies exploring the therapeutic role of immunomodulation …
severe COVID-19, with several studies exploring the therapeutic role of immunomodulation …
A comprehensive review of tocilizumab in COVID‐19 acute respiratory distress syndrome
Currently, the world is facing the pandemic of a novel strain of beta‐coronavirus known as
severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Acute respiratory distress …
severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Acute respiratory distress …
Addition of tocilizumab to the standard of care reduces mortality in severe COVID-19: a systematic review and meta-analysis
Introduction: Tocilizumab (TCZ) is an anti-interleukin-6 antibody that has been used for the
treatment of severe coronavirus disease 2019 (COVID-19). However, concrete evidence of …
treatment of severe coronavirus disease 2019 (COVID-19). However, concrete evidence of …
[HTML][HTML] Beneficial effect of corticosteroids in preventing mortality in patients receiving tocilizumab to treat severe COVID-19 illness
M Rubio-Rivas, M Ronda, A Padulles, F Mitjavila… - International Journal of …, 2020 - Elsevier
Objectives To assess the characteristics and risk factors for mortality in patients with severe
coronavirus disease-2019 (COVID-19) treated with tocilizumab (TCZ), alone or in …
coronavirus disease-2019 (COVID-19) treated with tocilizumab (TCZ), alone or in …
[HTML][HTML] Interleukin-6 (IL-6) inhibitors as therapeutic agents for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis
RT Pinzon, VO Wijaya, RB Buana - Journal of infection and public health, 2021 - Elsevier
Introduction Preliminary studies showed that coronavirus disease 2019 (COVID-19) disrupts
body immune system, including dysregulation of cytokine interleukin-6 (IL-6). IL-6 inhibitors …
body immune system, including dysregulation of cytokine interleukin-6 (IL-6). IL-6 inhibitors …